BICO News Feed

Discover the latest news from our business areas.

CELLINK Announces CTR Scientific as Exclusive Distributor in Mexico

Share on facebook
Share on twitter
Share on linkedin

The leading 3D bioprinting company, CELLINK, has entered the most important distribution partnership in Latin America in 2022 with widely known supplier, CTR Scientific, to be their exclusive distributor in Mexico. 

CELLINK, a global leader in bioprinting and biomaterials technologies, expands their Latin America (LATAM) operation by adding CTR Scientific as an exclusive distributor for its bioprinters, biodispensers, bioinks, printheads, accessories, consumables, and services in Mexico. 

CTR Scientific, founded in 1969 and headquartered in Mexico, has been dedicated to the distribution of laboratory equipment, materials and reagents. With more than 400 employees across 12 offices and 3 distribution centers throughout the country, CTR Scientific represents more than 300 brands within the life sciences field. 

“CTR shares CELLINK’s ambition – to improve the biofabrication of human organs and tissues and reduce the impact of organ shortages.” said Alfie Raymundo, LATAM Sales Manager at CELLINK. “As we continue our expansion through LATAM, we must continue to build relationships with experts in the region. Our partnership with CTR allows us to get closer to customers in the LATAM market and helps us further the impact of bioprinting and 3D cell culture. We couldn´t be happier about this partnership.” 

This new partnership is noteworthy and important for the region and will accelerate the bioprinting industry in Mexico using CELLINK´s products and services, directly impacting 100+ institutions and companies over the coming years. Through this partnership, CTR also reinforces its position as the leading life sciences products and services supplier, and the most innovative and visionary one throughout Mexico.  

“The first time I saw a 3D bioprinter in-action, it was CELLINK’s BIO X. I couldn’t believe what I was seeing. It seemed like rocket-science!” said Mr. Abelardo Perches, CEO at CTR Scientific. “We are already one step closer to personalized treatments for patients, fabricating tissues and organs, and even printing meat without harming animals. Now, CELLINK and CTR are closer to making it a reality in Mexico. It’s not rocket-science anymore!” 

Rubén Manuel Briseño, CTO at CTR Scientific expresses, “We are very excited about this partnership.  Within the next decades, 3D bioprinters will be one of the most efficient technologies solving health problems in laboratories, hospitals, clinics and more, improving the life and well-being of humans. CTR’s commitment to scientists and researchers in Mexico is to boost science through the next generation of technologies, and this partnership with CELLINK is further helping us in our mission of reinventing the life sciences industry across the country.” 

The commitment of creating innovation and educating the industry on the most efficient technologies globally is one which both companies are dedicated to and have created this partnership to continue doing so. 

“3D bioprinting technology is still in its initial phase in Mexico with many growing applications, therefore, promoting the development of this technology is imperative in the coming years to allow industry and academia access to such novel research and development tools.” said Alejandro Salinas, Field Application Specialist at CTR Scientific.   

While 3D bioprinting is gaining prominence across multiple research disciplines, it is still in the early stages of adoption in LATAM. This partnership is reducing the barriers for Mexico, allowing for hundreds of more labs and scientists to experiment with the technology, and opening the doors for continued innovation enabling the future of health, a key mission for both CELLINK and CTR Scientific, and this is just the beginning.

 

REGISTER HERE FOR THE UPCOMING WEBINAR

 

CELLINK in LATAM: 

With current partnerships in Brazil, Chile, Costa Rica, Perú, Bolivia, and Paraguay, and looking to expand in Colombia and Argentina, CELLINK is the leading bioprinting company in Latin America, working towards creating the future of health. By 2025, 250 bioprinters are expected to be installed throughout Latin America, and this is only just the beginning. 

 

About CELLINK 

CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016, it democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving industry. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 700 publications and are trusted by more than 1,000 academic, pharmaceutical and industrial labs. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models. Visit cellink.com to learn more. BICO is listed on the Nasdaq Stockholm Main Market under BICO. 

 

About Control Técnico y Representaciones 

Headquartered in Monterrey, Nuevo León, CTR Scientific is the leading supplier of equipment, products, and services within the life sciences industry in Mexico. Since 1969, they have been a strategic partners for many industries, including, biomedical research labs., pharma industry, clinical diagnosis facilities, private and public R&D Centers, academia, and biotech startups. In 2016, they became the first company in their field to receive the certification as Empresa Socialmente Responsable (Socially Responsible Company), from the Mexican Center for Philanthropy 

More news

June 27, 2022 | Cytena

CYTENA is officially the Innovator of the Year 2022

June 7, 2022 | Cytena

CYTENA enters long term OEM supply agreement with PAIA and launches the F.QUANT Titer high-throughput titer quantification assays for antibodies and Fc fusion proteins

June 6, 2022 | Cellink

Bioprinted Ear Successfully Transplanted into Patient

June 1, 2022 | Dispendix

ESHG & ISSCR 2022

June 1, 2022 | Scienion

SCIENION bestellt Frauke Hein als CEO

June 1, 2022 | Scienion

SCIENION Appoints Frauke Hein as CEO

May 30, 2022 | Dispendix

BICO Management Summit 2022

May 24, 2022 | Bico

Biosero, a Part of BICO Biosciences Is Awarded a New Patent for Laboratory Automation Scheduling Software

May 24, 2022 | Cellenion

Breakfast with Cellenion

May 16, 2022 | Bico

BICO joins The North American 3Rs Collaborative’s (NA3RsC) Microphysiological Systems (MPS) Initiative

May 12, 2022 | Bico

BICO Group Adds Senior IR Manager to Its Executive Management

May 11, 2022 | Dispendix

SLAS Europe 2022 – Dublin

May 6, 2022 | Cellenion

cellenONE Training & Workshop – June 2022

May 6, 2022 | Cellink

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology

May 5, 2022 | Cellink

CELLINK Announces CTR Scientific as Exclusive Distributor in Mexico

May 3, 2022 | Cytena

CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development

April 13, 2022 | Scienion

SCIENION GmbH feiert Grundsteinlegung für neue Unternehmenszentrale in Berlin Adlershof

March 3, 2022 | Cellenion

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence